Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04209725
Title A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SCRI Development Innovations, LLC
Indications

acute myeloid leukemia

Therapies

CPX-351 + Quizartinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
HCA Midwest Kansas City Missouri 64132 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
St. David's South Austin Medical Center Austin Texas 78704 United States Details
Texas Transplant Institute San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field